S. Zhang

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)

C. Zhou, Yi‐Long Wu, G. Chen et al. · Annals of Oncology · 2015 · 464 citations

Non-small-cell Lung Cancer, Medicine, Pathology +8

The Chinese version of ICIQ: A useful tool in clinical practice and research on urinary incontinence

Liang Huang, S. Zhang, Shiliang Wu et al. · Neurourology and Urodynamics · 2008 · 162 citations

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)

G. Chen, J. Feng, Caicun Zhou et al. · Annals of Oncology · 2013 · 119 citations · Full text

Medicine, Cancer Management, Phase Iii +6

Prevalence and risk factors of asymptomatic intracranial arterial stenosis in a community‐based population of <scp>C</scp>hinese adults

S. Zhang, Yong Zhou, Yifeng Zhang et al. · European Journal of Neurology · 2013 · 31 citations

A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN).

Yan Sun, Yajun Shi, L. Zhang et al. · Journal of Clinical Oncology · 2011 · 26 citations

Novel Therapy, Medicine, Receptor Tyrosine Kinase +15